Literature DB >> 23939025

Oversized AAV transductifon is mediated via a DNA-PKcs-independent, Rad51C-dependent repair pathway.

Matthew L Hirsch1, Chengwen Li, Isabella Bellon, Chaoying Yin, Sai Chavala, Marina Pryadkina, Isabelle Richard, Richard Jude Samulski.   

Abstract

A drawback of gene therapy using adeno-associated virus (AAV) is the DNA packaging restriction of the viral capsid (<4.7 kb). Recent observations demonstrate oversized AAV genome transduction through an unknown mechanism. Herein, AAV production using an oversized reporter (6.2 kb) resulted in chloroform and DNase-resistant particles harboring distinct "fragment" AAV (fAAV) genomes (5.0, 2.4, and 1.6 kb). Fractionation experiments determined that only the larger "fragments" mediated transduction in vitro, and relatively efficient transduction was also demonstrated in the muscle, the eye, and the liver. In contrast with concatemerization-dependent large-gene delivery by split AAV, fAAV transduction is independent of the catalytic subunit of DNA-dependent protein kinase (DNA-PKcs) in vitro and in vivo while disproportionately reliant on the DNA strand-annealing protein Rad51C. Importantly, fAAV's unique dependence on DNA repair proteins, compared with intact AAV, strongly suggests that the majority of oversized AAV transduction is mediated by fragmented genomes. Although fAAV transduction is less efficient than intact AAV, it is enhanced fourfold in muscle and sevenfold in the retina compared with split AAV transduction. Furthermore, fAAV carrying codon-optimized therapeutic dysferlin cDNA in a 7.5 kb expression cassette restored dysferlin levels in a dystrophic model. Collectively, oversized AAV genome transduction requires unique DNA repair pathways and offers an alternative, more efficient strategy for large-gene therapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23939025      PMCID: PMC3863795          DOI: 10.1038/mt.2013.184

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  44 in total

1.  Host cell DNA repair pathways in adeno-associated viral genome processing.

Authors:  Vivian W Choi; Douglas M McCarty; R Jude Samulski
Journal:  J Virol       Date:  2006-11       Impact factor: 5.103

2.  Packaging capacity of adeno-associated virus serotypes: impact of larger genomes on infectivity and postentry steps.

Authors:  Joshua C Grieger; Richard J Samulski
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

3.  Production and characterization of adeno-associated viral vectors.

Authors:  Joshua C Grieger; Vivian W Choi; R Jude Samulski
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

4.  Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions.

Authors:  C Summerford; R J Samulski
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

5.  Isolation and cross-sensitivity of X-ray-sensitive mutants of V79-4 hamster cells.

Authors:  N J Jones; R Cox; J Thacker
Journal:  Mutat Res       Date:  1987-05       Impact factor: 2.433

6.  In vitro packaging of adeno-associated virus DNA.

Authors:  X Zhou; N Muzyczka
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

7.  Cloning of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells.

Authors:  R J Samulski; K I Berns; M Tan; N Muzyczka
Journal:  Proc Natl Acad Sci U S A       Date:  1982-03       Impact factor: 11.205

8.  Loss of the catalytic subunit of the DNA-dependent protein kinase in DNA double-strand-break-repair mutant mammalian cells.

Authors:  S R Peterson; A Kurimasa; M Oshimura; W S Dynan; E M Bradbury; D J Chen
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-11       Impact factor: 11.205

9.  The role of DNA-PKcs and artemis in opening viral DNA hairpin termini in various tissues in mice.

Authors:  Katsuya Inagaki; Congrong Ma; Theresa A Storm; Mark A Kay; Hiroyuki Nakai
Journal:  J Virol       Date:  2007-08-08       Impact factor: 5.103

10.  Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose.

Authors:  Zhijian Wu; Junjiang Sun; Taiping Zhang; Chaoying Yin; Fang Yin; Terry Van Dyke; Richard J Samulski; Paul E Monahan
Journal:  Mol Ther       Date:  2007-12-04       Impact factor: 11.454

View more
  34 in total

1.  Genome editing in human stem cells.

Authors:  Susan M Byrne; Prashant Mali; George M Church
Journal:  Methods Enzymol       Date:  2014       Impact factor: 1.600

Review 2.  Adeno-associated Virus as a Mammalian DNA Vector.

Authors:  Max Salganik; Matthew L Hirsch; Richard Jude Samulski
Journal:  Microbiol Spectr       Date:  2015-08

3.  Dual adeno-associated virus vectors result in efficient in vitro and in vivo expression of an oversized gene, MYO7A.

Authors:  Frank M Dyka; Sanford L Boye; Vince A Chiodo; William W Hauswirth; Shannon E Boye
Journal:  Hum Gene Ther Methods       Date:  2014-04       Impact factor: 2.396

4.  Efficient central nervous system AAVrh10-mediated intrathecal gene transfer in adult and neonate rats.

Authors:  J Hordeaux; L Dubreil; J Deniaud; F Iacobelli; S Moreau; M Ledevin; C Le Guiner; V Blouin; J Le Duff; A Mendes-Madeira; F Rolling; Y Cherel; P Moullier; M-A Colle
Journal:  Gene Ther       Date:  2015-01-15       Impact factor: 5.250

Review 5.  Expressing Transgenes That Exceed the Packaging Capacity of Adeno-Associated Virus Capsids.

Authors:  Kyle Chamberlain; Jalish Mahmud Riyad; Thomas Weber
Journal:  Hum Gene Ther Methods       Date:  2016-02       Impact factor: 2.396

6.  Optimization of adeno-associated virus vector-mediated gene transfer to the respiratory tract.

Authors:  F Kurosaki; R Uchibori; N Mato; Y Sehara; Y Saga; M Urabe; H Mizukami; Y Sugiyama; A Kume
Journal:  Gene Ther       Date:  2017-03-27       Impact factor: 5.250

7.  Copackaging of multiple adeno-associated viral vectors in a single production step.

Authors:  Phillip A Doerfler; Barry J Byrne; Nathalie Clément
Journal:  Hum Gene Ther Methods       Date:  2014-09-19       Impact factor: 2.396

8.  Inhibition of antigen presentation during AAV gene therapy using virus peptides.

Authors:  Wenwei Shao; Xiaojing Chen; Richard J Samulski; Matthew L Hirsch; Chengwen Li
Journal:  Hum Mol Genet       Date:  2018-02-15       Impact factor: 6.150

9.  Structure-Based Designed Nano-Dysferlin Significantly Improves Dysferlinopathy in BLA/J Mice.

Authors:  Telmo Llanga; Nadia Nagy; Laura Conatser; Catherine Dial; R Bryan Sutton; Matthew L Hirsch
Journal:  Mol Ther       Date:  2017-06-16       Impact factor: 11.454

10.  Delivering Transgenic DNA Exceeding the Carrying Capacity of AAV Vectors.

Authors:  Matthew L Hirsch; Sonya J Wolf; R J Samulski
Journal:  Methods Mol Biol       Date:  2016
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.